Shisi Pharmaceutical Group (02005): Bilastine and sodium picosulfate were approved and registered by the State Drug Administration as raw materials for use in marketed formulations

Zhitongcaijing · 1d ago

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The Group's bilastine and picosulfate have been approved and registered by the China National Drug Administration as active ingredients for use in marketed formulations. Bilastine is mainly used for symptomatic treatment of urticaria, while sodium picosulfate is mainly used to clean the colon before surgical examinations such as colonoscopy.